Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 2 mins

Serum metabolic alterations associated with Chaihu-Longgu-Muli decoction in adolescents with insomnia: An exploratory untargeted metabolomics study

AI Summary
  • Chaihu-Longgu-Muli decoction treatment improved sleep quality, anxiety, and depression scores in adolescents with chronic insomnia.
  • Untargeted serum metabolomics identified altered metabolites, including higher sphinganine and 3-indoleacetonitrile, and lower choline, lysine lactam, cis-aconitic acid, sorbitol.
  • Metabolic shifts after CLMD moved toward healthy control levels; pathway analysis implicated intestinal IgA production, sphingolipid signalling, PPAR signalling, and bile secretion; findings exploratory.
Summarise with AI (MRCPsych/FRANZCP)

Medicine (Baltimore). 2026 Nov 6;105(45):e51296. doi: 10.1097/MD.0000000000051296.

ABSTRACT

Adolescent insomnia is common and is frequently accompanied by anxiety and depressive symptoms. Chaihu-Longgu-Muli decoction (CLMD) is used in traditional Chinese medicine prescriptions for insomnia; however, the biological changes associated with CLMD treatment in adolescents remain poorly characterized. This exploratory study investigated clinical symptom changes and corresponding serum metabolomic alterations associated with CLMD treatment in adolescents with chronic insomnia. Adolescents with chronic insomnia received either CLMD or cognitive behavioral therapy (CBT) according to the predefined treatment-allocation procedure. A healthy control group was included for baseline metabolic comparison. Sleep quality and emotional symptoms were assessed using the Pittsburgh Sleep Quality Index (PSQI), Self-Rating Anxiety Scale (SAS), and Self-Rating Depression Scale (SDS). Fasting serum samples collected before and after the intervention underwent untargeted metabolomic profiling using ultra-performance liquid chromatography coupled with tandem mass spectrometry. Candidate differential metabolites were identified using multivariate analysis together with a variable importance in projection score > 1.0 and nominal P < .05, followed by pathway enrichment analysis. Given the exploratory nature of the study, metabolomic findings were considered hypothesis-generating. Thirty adolescents were included in each intervention group, with an additional 10 healthy controls. Both CLMD and CBT groups showed improvements in PSQI, SAS, and SDS measures after treatment (all P < .05). Untargeted metabolomic profiling identified differences between adolescents with insomnia and healthy controls. Among the exploratory candidate metabolites, sphinganine and 3-indoleacetonitrile were higher in adolescents with insomnia, whereas ethylmethylacetic acid, choline, L-lysine 1,6-lactam, (R)-2-O-sulfolactate, cis-aconitic acid, and sorbitol were lower (all P < .05). Following CLMD treatment, these metabolites shifted toward levels observed in healthy controls. Exploratory pathway analysis implicated the intestinal immune network for IgA production, sphingolipid signaling, PPAR signaling, and bile secretion. CLMD treatment was associated with improvements in insomnia-related symptoms and concurrent changes in serum metabolic profiles in adolescents with chronic insomnia. The identified metabolites and pathways represent preliminary biological signals rather than validated biomarkers or established mechanisms. Larger studies with targeted quantitative metabolomics and independent validation are needed.

PMID:42994864 | DOI:10.1097/MD.0000000000051296

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD